Myocardial infarction

Have copious amounts of natural sugar Rhamnose to stay protected against myocardial diseases: L- Rhamnose protects against and promotes functional recovery after Myocardial Infarction:  L- Rhamnose (6-deoxy-L-Mannose) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 12/May/2019, 6.31 pm
Have copious amounts of natural sugar Rhamnose to stay protected against myocardial diseases: L- Rhamnose protects against and promotes functional recovery after Myocardial Infarction:  L- Rhamnose (6-deoxy-L-Mannose) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 12/May/2019, 6.31 pm 960 720

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Ribonucleic acid-based therapy protects against and promotes functional recovery after Myocardial Infarction:  LncRNA Mirt2 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 22/April/2019, 10.10 pm
Ribonucleic acid-based therapy protects against and promotes functional recovery after Myocardial Infarction:  LncRNA Mirt2 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 22/April/2019, 10.10 pm 960 720

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA ROR decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 24/March/2019, 5.22 pm
Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA ROR decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 24/March/2019, 5.22 pm 960 720

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Molecular therapy for heart regeneration and repair: Carvidiol (trade name: Coreg), used to treat congestive heart failure and high blood pressure, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 24/December/2017, 10.38 am
Molecular therapy for heart regeneration and repair: Carvidiol (trade name: Coreg), used to treat congestive heart failure and high blood pressure, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 24/December/2017, 10.38 am 960 720

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Molecular therapy for TIIDM and Metabolic defects: Carvedilol (brand name: Coreg), used to treat high blood pressure and congestive heart failure, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 23/December/2018, 11.19 pm
Molecular therapy for TIIDM and Metabolic defects: Carvedilol (brand name: Coreg), used to treat high blood pressure and congestive heart failure, increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 23/December/2018, 11.19 pm 960 720

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27701, USA; Department of…

read more

Mechanistic insights into how Carvedilol may aid in attenuating pathogenesis-associated with Myocardial infarction: Carvedilol (brand name: Coreg),  used in the treatment of high blood pressure and congestive heart failure, decreases IRF3 (Interferon regulatory transcription factor-3), GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up-regulation of its target gene, 23/December/2018, 5.47 pm
Mechanistic insights into how Carvedilol may aid in attenuating pathogenesis-associated with Myocardial infarction: Carvedilol (brand name: Coreg),  used in the treatment of high blood pressure and congestive heart failure, decreases IRF3 (Interferon regulatory transcription factor-3), GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up-regulation of its target gene, 23/December/2018, 5.47 pm 960 720

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more
Start Typing